COMPOUNDS FOR THE TREATMENT OF LEISHMANIA INFECTIONS (MACHINE-TRANSLATION BY GOOGLE TRANSLATE, NOT LEGALLY BINDING)

The compounds of the invention produce less toxicity and fewer side effects in the patient. The compounds of the invention are pharmaceutically acceptable salts, prodrugs and/or solvates, as well as pharmaceutical compositions containing them. They can be used together with other drugs, or additional active ingredients, to provide a combination therapy. This new result has good specificity for the Leishmania parasite and would be a competitive advantage for that pharmaceutical company that would manufacture an active ingredient for the formulation of a leishmanicidal drug. Given the similarity of the different species of Leishmania, the compounds of the invention are used for the treatment of any type of leishmaniasis. Both visceral (LV) and mucocutaneous (LMC). The therapeutic composition can be prepared in solid form or aqueous suspension, in a pharmaceutically acceptable diluent. It can be administered by any appropriate route of administration: oral, topical, rectal or parenteral.